Changelog: Created draft rewrite on 2025-12-09; revised references and structure.
Platelet-Rich Plasma (PRP) is an autologous blood product containing a supra-physiological concentration of platelets and growth factors, widely used in orthopedics, dermatology, and dentistry to promote tissue repair and regeneration. By concentrating platelets from a patient's own blood, PRP therapy aims to deliver a potent cocktail of bioactive proteins directly to the site of injury or aging, accelerating healing processes that might otherwise be slow or incomplete.
PRP is defined as a volume of autologous plasma that has a platelet concentration above baseline—typically 3 to 5 times the normal count (which ranges from 150,000 to 400,000/µL). A therapeutic PRP preparation often targets a concentration of at least 1,000,000 platelets/µL[1].
The composition of PRP extends beyond platelets. Depending on the preparation method, it may contain varying levels of:
Platelets are anucleate cell fragments derived from megakaryocytes in the bone marrow. While primarily known for hemostasis (clotting), they are also reservoirs of growth factors stored in intracellular -granules. Upon activation (either naturally by collagen/thrombin or artificially by calcium chloride), these granules degranulate, releasing their bioactive cargo[2].
PRP preparation is not standardized, leading to significant variability in clinical outcomes. The general process involves:
The presence of leukocytes significantly influences the biological effect of PRP:
The therapeutic potential of PRP rests on the delivery of growth factors (GFs) that modulate the healing cascade. Key factors include:
| Growth Factor | Primary Function |
|---|---|
| PDGF (Platelet-Derived Growth Factor) | Chemotaxis for macrophages/fibroblasts; stimulates collagen synthesis and proliferation. |
| TGF- (Transforming Growth Factor-beta) | Regulates cell proliferation/differentiation; stimulates ECM production (collagen, proteoglycans). |
| VEGF (Vascular Endothelial Growth Factor) | Potent stimulator of angiogenesis (new blood vessel formation). |
| IGF-1 (Insulin-like Growth Factor 1) | Promotes cell survival, proliferation, and matrix synthesis. |
| EGF (Epidermal Growth Factor) | Stimulates epithelial cell proliferation and migration. |
Biological Effects:
Evidence Grade: Moderate
PRP is increasingly regarded as a viable option for mild-to-moderate knee OA (Kellgren-Lawrence grades 1–3).
Evidence Grade: Low to Moderate (Condition Dependent)
Evidence Grade: Moderate
PRP is used to stimulate hair follicle stem cells and prolong the anagen (growth) phase.
Evidence Grade: Low to Moderate
Often marketed as the "Vampire Facial" when combined with microneedling.
Since PRP is autologous, the risk of immunogenic reactions or disease transmission is virtually zero.
There is a theoretical concern that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) inhibit platelet function (COX-1 inhibition) and may blunt the growth factor release or the inflammatory phase necessary for healing.
Post-injection protocols vary but generally include:
PRP represents a paradigm shift from "suppressing symptoms" (e.g., corticosteroids) to "promoting repair." However, it is not a magic bullet. Efficacy is highly dependent on:
Standardization of preparation protocols remains the most critical gap in the field. Until then, "PRP" refers to a family of products rather than a single standardized drug.
Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225-228. PMID: 11813662 ↩︎ ↩︎
Sundman EA, Cole BJ, Karas V, Della Valle C, Tetreault MW, Mohammed HO, Fortier LA. The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. Am J Sports Med. 2014;42(1):35-41. DOI: 10.1177/0363546513507766 ↩︎ ↩︎
Fadadu PP, Mazzola AJ, Fletcher CW, Jeyakumar V. Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization. HSS J. 2019;15(2):139-152. DOI: 10.1007/s11420-018-9637-z ↩︎
Lana JF, Weglein A, Sampson SE, et al. Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. J Stem Cells Regen Med. 2016;12(2):69-78. PMID: 28058027 ↩︎
Bensa A, Previtali D, Sangiorgio A, et al. PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Meta-analysis of Randomized Controlled Trials. Am J Sports Med. 2025;53(3):745-754. DOI: 10.1177/03635465241246524 ↩︎ ↩︎
Malcangi G, Inchingolo AM, Inchingolo AD, et al. The Role of Platelet Concentrates and Growth Factors in Facial Rejuvenation: A Systematic Review with Case Series. Medicina. 2025;61(1):84. DOI: 10.3390/medicina61010084 ↩︎ ↩︎
McLarnon M, Heron N. Intra-articular platelet-rich plasma (PRP) injections versus corticosteroid injections for knee osteoarthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2021;22(1):550. DOI: 10.1186/s12891-021-04398-z ↩︎
Fitzpatrick J, Bulsara M, Zheng MH. The Effectiveness of Platelet-Rich Plasma in the Treatment of Tendinopathy: A Meta-analysis of Randomized Controlled Clinical Trials. Am J Sports Med. 2017;45(1):226-233. DOI: 10.1177/0363546516643716 ↩︎
Gupta A, et al. Comparative Efficacy and Safety of Platelet Rich Plasma (PRP) versus Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. Aesthetic Plast Surg. 2025. DOI: 10.1007/s00266-025-05394-7 ↩︎